Esomeprazole for relief of upper gastrointestinal symptoms associated with continuous use of NSAIDs

Study identifier:D9617C00001

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Efficacy of esomeprazole 40 mg once daily versus placebo & esomeprazole 20 mg once daily versus placebo in treatment for relief of upper gastrointestinal symptoms associated with continuous use of NSAIDs including COX-2 selective NSAIDs

Medical condition

GERD

Phase

Phase 3

Healthy volunteers

No

Study drug

Esomeprazole

Sex

All

Actual Enrollment

808

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Jan 2001
Primary Completion Date: 01 Aug 2002
Study Completion Date: 01 Aug 2002

Study design

Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Jan 2011 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria